Denosumab and osteonecrosis of the jaws - The pharmacology, pathogenesis and a report of two cases

Australian Dental Journal

Volumn 59, Issue 4, 2014, Pages 516-519

  O'Halloran, M ^a   Boyd, N M ^a   Smith, A ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b Oral and Maxillofacial Surgery Private Practice   (Australia)

Author keywords

bisphosphonate related osteonecrosis of the jaws; Bisphosphonates; denosumab; denosumab associated osteonecrosis of the jaws; necrosis of the jaws

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR;

AGED; ANTAGONISTS AND INHIBITORS; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE NECROSIS; CASE REPORT; CHEMICALLY INDUCED; FEMALE; HUMAN; JAW DISEASE; MALE; MIDDLE AGED;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; DIPHOSPHONATES; FEMALE; HUMANS; JAW DISEASES; MALE; MIDDLE AGED; OSTEONECROSIS; RANK LIGAND;

EID: 84929990760     PISSN: 00450421     EISSN: 18347819     Source Type: Journal    
DOI: 10.1111/adj.12217     Document Type: Article

References (28)

1. Qi WX, Tang LN, He AN, Yao Y, Shen Z,. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol 2014; 19: 403-410.
2. Lespessailles E,. Bisphosphonates and glucocorticoid-induced osteoporosis: efficacy and tolerability. Joint Bone Spine 2013; 80: 258-264.
3. Hinchy NV, Jayaprakash V, Rossitto RA, et al,. Osteonecrosis of the jaw-Prevention and treatment strategies for oral health professionals. Oral Oncol 2013; 49: 878-886.
4. Dodson TB,. Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009; 67 (5 Suppl): 44-52.
5. Kühl S, Walter C, Acham S, Pfeffer R, Lambrecht JT,. Bisphosphonate-related osteonecrosis of the jaws-a review. Oral Oncol 2012; 48: 938-947.
6. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B,; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 2009; 67 (5 Suppl): 2-12.
7. Aghaloo TL, Felsenfeld AL, Tetradis S,. Osteonecrosis of the jaw in a patient on Denosumab. J Oral Maxillofac Surg 2010; 68: 959-963.
8. Taylor KH, Middlefell LS, Mizen KD,. Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg 2010; 48: 221-223.
9. Rachner TD, Platzbecker U, Felsenberg D, Hofbauer LC,. Osteonecrosis of the jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy. Mayo Clin Proc 2013; 88: 418-419.
10. Arrain Y, Masud T,. A current update on osteonecrosis of the jaw and bisphosphonates. Dent Update 2011; 38 (672-676): 678.
11. Fleisher KE, Jolly A, Venkata UD, Norman RG, Saxena D, Glickman RS,. Osteonecrosis of the jaw onset times are based on the route of bisphosphonate therapy. J Oral Maxillofac Surg 2013; 71: 513-519.
12. Malan J, Ettinger K, Naumann E, Beirne OR,. The relationship of denosumab pharmacology and osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 114: 671-676.
13. Kyrgidis A, Toulis KA,. Denosumab-related osteonecrosis of the jaws. Osteoporos Int 2011; 22: 369-370.
14. Yamashita J, McCauley LK,. Antiresorptives and osteonecrosis of the jaw. J Evid Based Dent Pract 2012; 12 (3 Suppl): 233-247.
15. Marx RE,. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-1117.
16. Sivolella S, Lumachi F, Stellini E, Favero L,. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease. Anticancer Res 2013; 33: 1793-1797.
17. Migliorati CA, Epstein JB, Abt E, Berenson JR,. Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review. Nat Rev Endocrinol 2011; 7: 34-42.
18. Assael LA,. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies. J Oral Maxillofac Surg 2009; 67 (5 Suppl): 35-43.
19. Diz P, Lõpez-Cedrún JL, Arenaz J, Scully C,. Denosumab-related osteonecrosis of the jaw. J Am Dent Assoc 2012; 143: 981-984.
20. Otto S, Baumann S, Ehrenfeld M, Pautke C,. Successful surgical management of osteonecrosis of the jaw due to RANK-ligand inhibitor treatment using fluorescence guided bone resection. J Craniomaxillofac Surg 2013; 41: 694-698.
21. Saad F, Brown JE, Van Poznak C, et al,. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012; 23: 1341-1347.
22. Epstein MS, Ephros HD, Epstein JB,. Review of current literature and implications of RANKL inhibitors for oral health care providers. Oral Surg Oral Med Oral Pathol Oral Radiol 2013; 116: e437-442.
23. Weinstein RS,. Glucocorticoid-induced osteonecrosis. Endocrine 2012; 41: 183-190.
24. Lipton A, Fizazi K, Stopeck AT, et al,. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012; 48: 3082-3092.
25. Weinstein RS,. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am 2012; 41: 595-611.
26. Akhtar NH, Afzal MZ, Ahmed AA,. Osteonecrosis of jaw with the use of Denosumab. J Cancer Res Ther 2011; 7: 499-500.
27. Anastasilakis AD, Toulis KA, Polyzos SA, Anastasilakis CD, Makras P,. Long-term treatment of osteoporosis: safety and efficacy appraisal of Denosumab. Ther Clin Risk Manag 2012; 8: 295-306.
28. Aghaloo TL, Dry SM, Mallya S, Tetradis S,. Stage 0 Osteonecrosis of the jaw in a patient on Denosumab. J Oral Maxillofac Surg 2014; 72: 702-716.